paroxetine has been researched along with 2019 Novel Coronavirus Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kodvanj, I; Trkulja, V | 1 |
| Bhatia, MS; Daral, A; Goyal, S; Singh, A | 1 |
2 other study(ies) available for paroxetine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Outpatients prescribed with fluvoxamine around the time of COVID-19 diagnosis are not at a reduced risk of subsequent hospitalization and death compared to their non-prescribed peers: population-based matched cohort study.
Topics: Adult; Bayes Theorem; Cohort Studies; COVID-19; COVID-19 Drug Treatment; COVID-19 Testing; Fluvoxamine; Hospitalization; Humans; Outpatients; Paroxetine | 2023 |
COVID-19 Pandemic-Induced Panic Disorder.
Topics: Adult; Betacoronavirus; Clonazepam; Coronavirus Infections; COVID-19; Humans; Male; Pandemics; Panic Disorder; Paroxetine; Pneumonia, Viral; SARS-CoV-2 | 2020 |